MAR 1 2 2007

PTO/SB/08A (07-05) PTOSEROA (I/O.5)
Approved for use through 07/10/00.0 Mode Set 1031
U.S. Palara all Trademan's Office; U.S. DEPARTMENT OF COMMENSE.
U.S. Palara all Trademan's Office; U.S. DEPARTMENT OF COMMENSE.
U.S. Palara all Trademan's Office; U.S. DEPARTMENT OF COMMENSE.
Substitute for form 1448PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Application Number 10/536.628 Filing Date Nov/27/2003 First Named Inventor HAJ-YEHIA, Abdullah Ibrahim Art Unit 1614 Examiner Name Attorney Docket Number 0-06-227

Examiner Initials*	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	No.	Number-Kind Code ^{2 (F brown)}			
Y.C./		US- 6,232,331	2001-05-15	Torrent Pharmaceutical Ltd.	
1		US- 6,248,895	2001-06-19	Torrent Pharmaceuticals Ltd.	
		US- 6,444,702	2002-09-03	NeuroMolecular, Inc.	
1	_	US- 6,417,207	2002-07-09	NitroMed, Inc.	
		US- 6,255,296	2001-07-03	EndoMatrix, Inc.	
1		US. 6,051,571	2000-04-18	Centaur Pharmaceuticals, Inc.	
		US- 6,440,961	2002-08-27	Dr. Reddy's Research Foundation	
1-		US- 6,429,219	2002-08-06	Chronorx, LLC	
_		US- 6,423,724	2002-07-23	The Procter & Gamble Company	
\top		US- 6,248,895	2001-06-19	Torrent Pharmaceuticals Ltd.	
\top		US- 6,458,840	2002-10-01	American Biogenetic Sciences, Inc.	
1		US- 6,458,830	2002-10-01	Merck Sharp & Dohme Ltd.	
	T	US- 6,444,702	2002-09-03	NeuroMolecular, Inc.	
\neg		US- 6,376,550	2002-04-23	ASTA Medica AG	
		US- 6,414,505	2002-07-02	Compaq Information Technologies Gro	
\neg		US- 6,403,627	2002-06-11	Oklahoma Medical Research Foundation	
.1.		US- 6,355,689	2002-03-12	SmithKline Beecham Corporation	
\mathbf{A}		US- 6,331,553	2001-12-18	Chugai Selyaku Kabushiki Kalsha	
/Y.C./		^{US-} 6,265,441	2001-07-24	Olesen, Jes	

Examiner initiats*	Cite No.1	Foreign Palent Document	Publication Date	Name of Petantee or Applicant of Cited Document ANDERSON, JUDY, E et al	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Τ*
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if Anown)	MM-DD-YYYY			
/Y.C./	,	WO 00/53191	2001-09-13			
1	,	WO 96/32946	1996-10-24	GARVEY, David, S. et al		
_	•	WO 97/31654	1997-09-04	NICOX S.A.		L
	,	WO 99/61430	1999-12-02	SANKARANARAYANAN, Ala		
VI	•	WO 99/61018	1999-12-02	SANKARANARAYANAN, Ala		L
7 V.	-	WO 00/67754	2000-11-16	NITROMED, INC.		

/Yong Chu/ 07/18/2008 Considered

Transistion is addressed.

Transistion is addressed.

Transistion is addressed in supprised by 27 CFR 197 and 1.86. The information is required to obtain or retain is based by the policy which is to list (pind by the LUSTO by process) an application. Conferentiating is promised by \$50 LISC. 122 and 27 CFR 1.14. This coldination is estimated to listed 2 bones to complete including planking, preparing, and submitting in the completed application form to the LUSTO. These 44 may depending upon the similarity and in a similarity of the standard control or the control of the